1. Prognostic impact of severe anemia (hemoglobin <10g/dL) during treatment with dual antiplatelet therapy after hospital discharge for acute coronary syndrome
- Author
-
C Oliveira, C.G. Braga, Isabel Campos, Paloma Lys de Medeiros, C Pires, R Flores, F Mane, and António Gaspar
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,Ejection fraction ,business.industry ,Anemia ,medicine.medical_treatment ,Percutaneous coronary intervention ,medicine.disease ,Revascularization ,Heart failure ,Internal medicine ,Diabetes mellitus ,Cardiology ,Medicine ,Hemoglobin ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction In recent years, the use of invasive strategies has become the generalized approach in the management of patients with acute coronary syndrome (ACS), justified by the associated prognostic benefit due to reduced mortality and the evolution of percutaneous coronary intervention (PCI). However, the benefits of an invasive approach in ACS are unclear in the population with significant anemia, as anemia is strongly associated with increased risk of morbidity and mortality in these patients. Aim To determine the ischaemic vs. bleeding risks from patients with severe anemia (hemoglobin Methods From a national multicentre registry, we analyzed 17 370 ACS pts. Pts were divided into two groups: group 1 - pts with severe anemia (hemoglobin Results The sample consisted in 73.4% men and 26.6% women, with mean age of 66±14 years. The incidence of severe anemia was 3.2%. Group 1 pts were older (75±12 vs 66±14, p Conclusion We objected a low prevalence of ACS patients with severe anemia undergoing PCI (52.2%) but the incidence of ICP in these complex patients has increased in recent years, mainly due to the evolution of PCI over the last 40 years. Severe anemia was strongly associated with increased risk of morbidity and mortality in ACS pts. Funding Acknowledgement Type of funding source: None
- Published
- 2020
- Full Text
- View/download PDF